Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
-15°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eaton Vance Ohio Municipal Income Trust
(NQ:
EVO
)
4.630
+0.050 (+1.09%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eaton Vance Ohio Municipal Income Trust
< Previous
1
2
3
4
Next >
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
August 04, 2022
Via
ACCESSWIRE
Evotec SE Reports Results of Annual General Meeting 2022
June 22, 2022
HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the...
From
Evotec SE
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Evotec Enters a Drug Discovery Collaboration with Janssen
June 14, 2022
HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen...
From
Evotec SE
Via
AccessWire
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
May 30, 2022
CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING
From
Evotec AE
Via
AccessWire
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
May 19, 2022
HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global...
From
Evotec AG
Via
AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
May 10, 2022
HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and...
From
Evotec AG
Via
AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
May 10, 2022
- 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS - COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING...
From
Evotec AG
Via
AccessWire
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Evotec AG
Via
AccessWire
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
April 12, 2022
- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY...
From
Evotec AG
Via
AccessWire
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
April 08, 2022
- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A...
From
Evotec AG
Via
AccessWire
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
April 05, 2022
HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April...
From
Evotec AG
Via
AccessWire
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
March 21, 2022
- FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC - PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR...
From
Evotec AG
Via
AccessWire
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
March 02, 2022
- LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE - ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND...
From
Evotec AG
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
March 01, 2022
- EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL - THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN...
From
Evotec AG
Via
AccessWire
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
February 04, 2022
HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by...
From
Evotec AG
Via
AccessWire
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
January 25, 2022
- PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS - AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS...
From
Evotec AG
Via
AccessWire
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases
January 18, 2022
- COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS - LILLY HAS THE RIGHT...
From
Evotec AG
Via
AccessWire
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
January 03, 2022
- EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 - EVOTEC IS DEVELOPING A HIGHLY POTENT...
From
Evotec AG
Via
AccessWire
Exposures
COVID-19
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
November 18, 2021
From
EQRx
Via
Business Wire
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership
November 18, 2021
- EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM - PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND...
From
Evotec AG
Via
AccessWire
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
November 10, 2021
- THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE (Frankfurt Stock...
From
Evotec AG
Via
AccessWire
Exposures
Product Safety
Evotec SE Announces Closing of Public Offering
November 09, 2021
HAMBURG, GERMANY / ACCESSWIRE / November 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today the closing of its public offering on 08...
From
Evotec AG
Via
AccessWire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.